Serenity BioWorks is developing an immune-compatible gene therapy platform. We have identified key receptors on macrophages that potently modulate macrophage activity. We have successfully demonstrated that targeting these receptors avoids pro-inflammatory responses initiated by innate receptors or the inflammasome.